medwireNews: The phase 3 LIBRETTO-531 trial has demonstrated the superiority of selpercatinib, a highly selective RET kinase inhibitor, over approved multikinase inhibitors in people with advanced RET-mutant medullary thyroid cancer.
23-10-2023 | Thyroid Cancer | Editor's Choice | News